1:1 Mentorship
Strictly 1:1 Personalised Mentorship for UPSC CSE & UPPSC PCSOne dedicated mentor, only for you — no batches, no crowdLimited capacity: only a few mentorship seats open each monthA 1:1 session with your mentor every day + 24/7 chat supportMains answers evaluated live, 1:1, with spoken feedbackMentors who have personally written Mains & faced the interviewGuidance in English & HindiBook your free counselling call →

Drug Regulation Reforms in India: Drugs Rules, Antimicrobials and Supply Chain Explained for UPSC

In short: India supplies medicines to much of the world, but deaths linked to contaminated cough syrups and repeated findings of substandard drugs have exposed gaps in its regulatory system. The Health Ministry’s draft amendments of November 2026 target three weak points: storage and distribution, the licensing of antimicrobials and the wholesale trade in bulk drugs. Their success will depend on State drug regulators, testing laboratories and enforcement.

Syllabus: GS Paper 2: Issues relating to development and management of health; Government policies and interventions; Statutory and regulatory bodies · Source: PIB, Ministry of Health and Family Welfare · 19 November 2026

Main law
Drugs and Cosmetics Act, 1940
Central regulator
CDSCO (headed by DCGI)
Revised Schedule M
Notified 28 December 2023

Why is it in the news?

On 19 November 2026 the Ministry of Health and Family Welfare announced four draft amendments for public comment. They propose incorporating Good Storage and Distribution Practices (GSDP) into the Drugs Rules, 1945; amending the New Drugs and Clinical Trials (NDCT) Rules, 2019 to include antimicrobials in the definition of “new drug”; introducing a separate licence for the wholesale sale of bulk drugs; and continuing certain exemptions under the revised Schedule M for medicinal gases, empty gelatin capsules and disinfectant fluids.

The proposed changes

ProposalWhat it does
GSDP in the Drugs RulesMakes CDSCO’s storage and distribution guidance binding across procurement, storage, transport and record-keeping, to prevent deterioration, contamination, mix-ups, falsification and diversion
Antimicrobials as “new drugs” (draft G.S.R. 983(E))Manufacturers must get permission from the Central Licensing Authority before applying to a State Licensing Authority, so that bioequivalence and stability studies are checked
Separate licence for bulk drugs (draft G.S.R. 987(E))New Forms 19-BC and 20-BC for wholesale of bulk drugs, including NDPS substances, under a competent person; agreed by the DCC and DTAB
Schedule M flexibility (draft G.S.R. 985(E))Continues pre-revision exemptions for medicinal gases, empty gelatin capsules and disinfectant fluids, on DTAB’s advice

The regulatory structure

  • Law: The Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 govern import, manufacture, distribution and sale.
  • Centre: The CDSCO, under the Directorate General of Health Services, approves new drugs and clinical trials and regulates imports.
  • States: State Licensing Authorities license manufacturing units and pharmacies and carry out most inspections.
  • Advisory bodies: The Drugs Technical Advisory Board advises on technical matters, and the Drugs Consultative Committee secures uniformity among States.

Health and safety dimension

Quality failures can kill. Child deaths linked to cough syrups contaminated with diethylene glycol were reported in The Gambia and Uzbekistan in 2022 and in Madhya Pradesh in 2025, and drug regulators regularly flag samples that are “not of standard quality”. Quality can also be lost after manufacture: vaccines, insulin and many antibiotics lose potency if stored at the wrong temperature. Substandard antimicrobials that deliver a low dose let bacteria survive and develop resistance, which links drug quality directly to antimicrobial resistance.

Economic and governance dimension

  • Global trust: India is a major supplier of generic medicines and vaccines, so quality scandals hurt exports and the country’s reputation.
  • MSMEs: Small manufacturers find upgrading to the revised Schedule M costly, which is why timelines were extended for them.
  • Fragmentation: Licensing by many State regulators with uneven capacity leads to different standards across States.
  • Diversion: A common wholesale licence for formulations and bulk drugs makes it harder to track movement of NDPS substances and raw antibiotics.

Critical Analysis

The proposals address real gaps, and moving from guidance to binding rules for storage and distribution is overdue. Central approval for antimicrobials should also stop the practice of licensing copies without proper studies. But rules alone do not change outcomes. Most State drug control departments are short of inspectors and testing laboratories, so new obligations may go unchecked. Central permission for every antimicrobial product could slow approvals and burden the CDSCO, unless its capacity grows. Small wholesalers and distributors may struggle with documentation and cold-chain requirements, which could raise costs or push some out of business. The Schedule M exemptions are defended as product-specific, but critics may see them as dilution. A comprehensive new law to replace the 1940 Act has been discussed for years, including a draft Bill in 2022, but has not yet been enacted.

Way Forward

  • Expand State drug inspectorates and testing laboratories, with central funding linked to performance.
  • Use track-and-trace systems, such as barcodes on drug packs, to follow medicines through the supply chain.
  • Give MSMEs technical and financial support to meet revised Schedule M and GSDP requirements.
  • Set time limits for central approvals of antimicrobials so that access to medicines is not delayed.
  • Publish test results and enforcement action, so that patients and buyers can see which firms fail.
  • Enact a modern drugs law with clear roles for the Centre and States and stronger penalties.

India’s reputation as a supplier of affordable medicines rests on trust in their quality. The new rules are a useful step, but they will work only if regulators have the people, laboratories and independence to enforce them.

Key Facts for Prelims

  • The Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 are the main laws on drug regulation.
  • The CDSCO is headed by the Drugs Controller General of India (DCGI) and works under the Directorate General of Health Services.
  • The New Drugs and Clinical Trials Rules were notified in 2019.
  • Revised Schedule M (Good Manufacturing Practices) was notified on 28 December 2023.
  • The Drugs Technical Advisory Board (DTAB) and the Drugs Consultative Committee (DCC) are statutory bodies under the 1940 Act.
  • The draft amendment on bulk drugs introduces Forms 19-BC and 20-BC.

Practice Questions

Q1. With reference to drug regulation in India, consider the following statements:
1. Schedule M of the Drugs Rules, 1945 deals with Good Manufacturing Practices.
2. The licence to manufacture most drugs is granted by the Central Drugs Standard Control Organisation.
Which of the statements given above is/are correct?

  1. 1 only
  2. 2 only
  3. Both 1 and 2
  4. Neither 1 nor 2
Show answer

Answer: (a) Statement 1 is correct. Statement 2 is wrong: State Licensing Authorities grant manufacturing licences for most drugs; the CDSCO approves new drugs and clinical trials.

Q2. The proposed amendment to the New Drugs and Clinical Trials Rules, 2019 announced in November 2026 seeks to include which of the following in the definition of “new drug”?

  1. Vaccines
  2. Antimicrobials
  3. Medical devices
  4. Ayurvedic medicines
Show answer

Answer: (b) The draft G.S.R. 983(E) proposes to include antimicrobials in the definition of new drug, so that central permission is needed before a State manufacturing licence.

Q. Recent incidents of substandard and contaminated medicines have raised questions about India’s drug regulatory system. Examine the gaps in the system and evaluate the reforms proposed in 2026. (15 marks, 250 words)

Approach: Introduce with India’s role as a supplier of generics and recent incidents. In the body, describe the Centre-State structure, the revised Schedule M and the 2026 proposals on GSDP, antimicrobials and bulk drugs, then gaps in capacity and enforcement. Conclude with institutional reforms and a modern law.

FAQs

What changes has the Health Ministry proposed in drug regulation?

In November 2026 the Ministry proposed adding Good Storage and Distribution Practices to the Drugs Rules, 1945, bringing antimicrobials under the definition of new drug in the NDCT Rules, 2019, and creating a separate wholesale licence for bulk drugs.

Why bring antimicrobials under the definition of new drug?

The Ministry said licences for antimicrobial products were sometimes granted without bioequivalence and stability studies, and substandard antimicrobials can spread resistance, so manufacturers would need permission from the Central Licensing Authority before a State licence.

What is the revised Schedule M?

Schedule M of the Drugs Rules, 1945 sets Good Manufacturing Practices; it was revised on 28 December 2023 to bring Indian standards closer to WHO-GMP, with requirements such as a pharmaceutical quality system and quality risk management.

Who regulates drugs in India?

Under the Drugs and Cosmetics Act, 1940, the CDSCO, headed by the Drugs Controller General of India, approves new drugs and clinical trials, while State Licensing Authorities license the manufacture and sale of most drugs.

हिंदी सारांश

स्वास्थ्य मंत्रालय ने नवंबर 2026 में औषधि नियमन में कई बदलाव प्रस्तावित किए। औषधि नियम, 1945 में भंडारण और वितरण की अच्छी प्रथाएँ जोड़ी जाएँगी, ताकि निर्माता से मरीज़ तक दवा की गुणवत्ता बनी रहे। रोगाणुरोधी दवाओं को नई औषधि एवं नैदानिक परीक्षण नियम, 2019 में नई औषधि की परिभाषा में लाने का प्रस्ताव है, जिससे राज्य लाइसेंस से पहले केंद्रीय अनुमति लेनी होगी। थोक औषधियों के लिए अलग लाइसेंस भी प्रस्तावित है। खाँसी की दवा से हुई मौतों के बाद ये क़दम अहम हैं, पर राज्यों में निरीक्षकों और प्रयोगशालाओं की कमी बड़ी चुनौती है।

Sources: PIB: GSDP to be incorporated into Drugs Rules, 1945 (19 Nov 2026); PIB: Amendment to NDCT Rules, 2019 on antimicrobials (19 Nov 2026); PIB: Separate licensing framework for wholesale of bulk drugs (19 Nov 2026); PIB: Schedule M flexibility for medicinal gases, capsules and disinfectants (19 Nov 2026).

Related reading on GSMitra: Antimicrobial Resistance in India Explained for UPSC, PIB News Today for UPSC: 19 November 2026, Daily Editorial Analysis 19 November 2026.

Revise this topic with a custom test in the GSMitra MCQ Test Builder, or get your Mains answers on it evaluated 1:1 through GSMitra mentorship. Prefer to talk first? Book a free consultation on WhatsApp.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top